RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/LT2013/000006, filed Mar 15, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,637,739 | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX In force · High confidence | Vilnius University | In force | High confidence | ||
| US 10,844,378 | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX In force · High confidence | Vilnius University | In force | High confidence | ||
| US 12,662,668 | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX In force · High confidence | Vilnius University | In force | High confidence | ||
| Application 14/683,443 | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX Abandoned Abandoned Feb 25, 2019 | Vilnius University | Abandoned | Abandoned Feb 25, 2019 | ||
| Application 14/743,764 | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX Abandoned Abandoned Aug 27, 2022 | Vilnius University | Abandoned | Abandoned Aug 27, 2022 | ||
| Application 19/680,140 | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX Pending Not granted | Vilnius University | Pending | Not granted |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Vilnius University.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.